Vol. 7, Issue 2, Part B (2025)

With the global burden of cancer continuing to rise, advancements in diagnostic technologies and modern anticancer therapies have significantly improved survival rates. However, while these agents are highly effective, they may also affect normal tissues, resulting in cytotoxicity, inflammation, and neurotoxicity that can profoundly impact patients’ quality of life. Ocular adverse effects from systemic chemotherapy remain under-recognized and may go undetected without dedicated ophthalmic assessment. Although not all toxicities can be prevented, timely evaluation and regular ophthalmic monitoring—integrated within the multidisciplinary oncology care pathway—are critical for early detection and management. This review provides an overview of the ocular toxicities associated with systemic anticancer therapies.